Share on StockTwits

Enzo Biochem (NYSE:ENZ) posted its quarterly earnings results on Monday. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.08, American Banking News reports. The company had revenue of $24.00 million for the quarter, compared to the consensus estimate of $22.80 million.

Shares of Enzo Biochem (NYSE:ENZ) traded down 0.65% during mid-day trading on Monday, hitting $4.59. The stock had a trading volume of 255,383 shares. Enzo Biochem has a 52-week low of $1.96 and a 52-week high of $4.80. The stock’s 50-day moving average is $4.00 and its 200-day moving average is $3.45. The company’s market cap is $195.4 million.

Enzo Biochem, Inc (NYSE:ENZ) is an integrated life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.